Press Releases
Information for the media and for our investors
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Formycon AG today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
February 7, 2023
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
Formycon AG today published positive preliminary efficacy and safety data from MAGELLAN-AMD Phase III clinical trial for FYB203, its proposed biosimilar to Eylea®.
February 6, 2023
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Formycon AG as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced the conclusion of a global license agreement with Fresenius Kabi AG.
February 2, 2023
Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
Munich – On the basis of the bookbuilding procedure carried out as part of the private placement, the Management Board, with the approval of the Supervisory Board, set a placement price of EUR 77.00 per new share, resulting in gross proceeds from the offering of EUR 70,070,000.00 before commissions and costs. The New Shares correspond to approximately 6.02% of the Company's currently issued share capital.
February 2, 2023
Formycon AG upsizes capital increase from authorized capital following strong demand
Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon” or “Company") announces that, following strong demand, the Company has decided to upsize their previously announced capital increase from authorized capital from approx. 5% to in total approx. 6% of the outstanding share capital.
February 1, 2023
Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) intends to issue approx. 5% of the issued share capital of the Company, representing approx. 750,000 new shares (the "New Shares").
February 1, 2023
Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), today announced the conclusion of a global license agreement with Fresenius Kabi AG (“Fresenius Kabi”).
February 1, 2023
Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that Klinge Biopharma GmbH, the exclusive owner of the global commercialization rights of FYB203, Formycon’s biosimilar candidate to Eylea® (aflibercept), has entered into a binding term sheet with Coherus BioSciences, Inc. (“Coherus”) for the exclusive commercialization of FYB203 in the United States (U.S.).
January 9, 2023